Helius Medical Technologies, Inc. (NASDAQ:HSDT) Sees Large Drop in Short Interest

Helius Medical Technologies, Inc. (NASDAQ:HSDT) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 89,800 shares, a drop of 5.5% from the November 15th total of 95,000 shares. Based on an average daily volume of 361,500 shares, the short-interest ratio is currently 0.2 days.

Helius Medical Technologies Price Performance

Shares of Helius Medical Technologies stock opened at $0.49 on Thursday. Helius Medical Technologies has a 1 year low of $0.37 and a 1 year high of $9.50. The firm’s 50-day moving average is $0.52 and its 200 day moving average is $0.73. The stock has a market cap of $1.82 million, a price-to-earnings ratio of -0.08 and a beta of 1.68.

Wall Street Analyst Weigh In

Separately, Maxim Group reissued a “hold” rating on shares of Helius Medical Technologies in a research report on Wednesday, October 16th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Armistice Capital LLC acquired a new stake in Helius Medical Technologies, Inc. (NASDAQ:HSDT) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned approximately 4.39% of Helius Medical Technologies at the end of the most recent quarter. Institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.